title: Survey of the effects of a column for adsorption of β2-microglobulin in patients with dialysis-related amyloidosis in Japan.
abstract: Dialysis-related amyloidosis is a serious complication of long-term hemodialysis. Its pathogenic mechanism involves accumulation of β2-microglobulin in the blood, which then forms amyloid fibrils and is deposited in tissues, leading to inflammation and activation of osteoclasts. Lixelle, a direct hemoperfusion column for adsorption of β2-microglobulin, has been available since 1996 to treat dialysis-related amyloidosis in Japan. However, previous studies showing the therapeutic efficacy of Lixelle were conducted in small numbers of patients with specific dialysis methods. Here, we report the results of a nationwide questionnaire survey on the therapeutic effects of Lixelle. Questionnaires to patients and their attending physicians on changes in symptoms of dialysis-related amyloidosis by Lixelle treatment were sent to 928 institutions that had used Lixelle, and fully completed questionnaires were returned from 345 patients at 138 institutions. The patients included 161 males and 184 females 62.9 ± 7.7 years age, who had undergone dialysis for 25.9 ± 6.2 years and Lixelle treatment for 3.5 ± 2.7 years. Based on self-evaluation by patients, worsening of symptoms was inhibited in 84.9-96.5% of patients. Of the patients, 91.3% felt that worsening of their overall symptoms had been inhibited, while attending physicians evaluated the treatment as effective or partially effective for 72.8% of patients. Our survey showed that Lixelle treatment improved symptoms or prevented the progression of dialysis-related amyloidosis in most patients.
authors: Office of President, Niigata University, Niigata, Japan. gejyo@med.niigata-u.ac.jp
authors: Fumitake
authors: F
authors: Gejyo
authors: Izumi
authors: I
authors: Amano
authors: Tetsuo
authors: T
authors: Ando
authors: Mari
authors: M
authors: Ishida
authors: Seiichi
authors: S
authors: Obayashi
authors: Hiroshi
authors: H
authors: Ogawa
authors: Toshihiko
authors: T
authors: Ono
authors: Yutaka
authors: Y
authors: Kanno
authors: Tateki
authors: T
authors: Kitaoka
authors: Kazutaka
authors: K
authors: Kukita
authors: Satoshi
authors: S
authors: Kurihara
authors: Motoyoshi
authors: M
authors: Sato
authors: Jeongsoo
authors: J
authors: Shin
authors: Masashi
authors: M
authors: Suzuki
authors: Susumu
authors: S
authors: Takahashi
authors: Yoshio
authors: Y
authors: Taguma
authors: Yoshiaki
authors: Y
authors: Takemoto
authors: Ryoichi
authors: R
authors: Nakazawa
authors: Takeshi
authors: T
authors: Nakanishi
authors: Hidetoshi
authors: H
authors: Nakamura
authors: Shigeko
authors: S
authors: Hara
authors: Makoto
authors: M
authors: Hiramatsu
authors: Ryuichi
authors: R
authors: Furuya
authors: Ikuto
authors: I
authors: Masakane
authors: Kenji
authors: K
authors: Tsuchida
authors: Yasuki
authors: Y
authors: Motomiya
authors: Hiroyuki
authors: H
authors: Morita
authors: Kunihiro
authors: K
authors: Yamagata
authors: Kunihiko
authors: K
authors: Yoshiya
authors: Tomoyuki
authors: T
authors: Yamakawa
mesh_terms: D000327:Adsorption; D000368:Aged; D000686:Amyloidosis / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D018450:Disease Progression; D005260:Female; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D011795:Surveys and Questionnaires; D013997:Time Factors; D001613:beta 2-Microglobulin / Q000378:metabolism*
chemical_list: D001613:beta 2-Microglobulin